MX2020005657A - Predictor de radioterapia de receptor de peptido usando un ensayo de expresion genica. - Google Patents

Predictor de radioterapia de receptor de peptido usando un ensayo de expresion genica.

Info

Publication number
MX2020005657A
MX2020005657A MX2020005657A MX2020005657A MX2020005657A MX 2020005657 A MX2020005657 A MX 2020005657A MX 2020005657 A MX2020005657 A MX 2020005657A MX 2020005657 A MX2020005657 A MX 2020005657A MX 2020005657 A MX2020005657 A MX 2020005657A
Authority
MX
Mexico
Prior art keywords
peptide receptor
gene expression
expression assay
receptor radiotherapy
predicting peptide
Prior art date
Application number
MX2020005657A
Other languages
English (en)
Inventor
Mark Kidd
Irvin Mark Modlin
Ignat Drozdov
Original Assignee
Liquid Biopsy Res Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liquid Biopsy Res Llc filed Critical Liquid Biopsy Res Llc
Publication of MX2020005657A publication Critical patent/MX2020005657A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención está dirigida a métodos para proporcionar una recomendación de tratamiento con radioterapia de receptor de péptido para un sujeto que tiene un tumor neuroendocrino, mediante la determinación del nivel de expresión de cada uno de al menos 9 biomarcadores que comprenden ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3 y ALG9. En algunas modalidades, los métodos pueden incluir además la determinación del nivel de expresión de cada uno de NAP1L1, NOL3 y TECPR2.
MX2020005657A 2017-11-30 2018-11-29 Predictor de radioterapia de receptor de peptido usando un ensayo de expresion genica. MX2020005657A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762592647P 2017-11-30 2017-11-30
PCT/US2018/062964 WO2019108734A1 (en) 2017-11-30 2018-11-29 Predicting peptide receptor radiotherapy using a gene expression assay

Publications (1)

Publication Number Publication Date
MX2020005657A true MX2020005657A (es) 2020-11-12

Family

ID=64665422

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005657A MX2020005657A (es) 2017-11-30 2018-11-29 Predictor de radioterapia de receptor de peptido usando un ensayo de expresion genica.

Country Status (11)

Country Link
US (2) US11744907B2 (es)
EP (1) EP3717667A1 (es)
JP (2) JP7344871B2 (es)
KR (1) KR20200092382A (es)
CN (1) CN111479931B (es)
AU (1) AU2018375376A1 (es)
BR (1) BR112020008680A2 (es)
CA (1) CA3080750A1 (es)
IL (1) IL274279A (es)
MX (1) MX2020005657A (es)
WO (1) WO2019108734A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111479931B (zh) 2017-11-30 2024-08-16 液体活检研究有限责任公司 使用基因表达测定预测肽受体放射治疗
TW202128995A (zh) 2019-10-10 2021-08-01 聖克里斯多福商液態生物檢體研究公司 用於生物樣品和ｒｎａ安定化之組成物、方法及套組
WO2024073652A1 (en) 2022-09-30 2024-04-04 Liquid Biopsy Research LLC Methods for neuroendocrine cancer detection in saliva

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX351779B (es) * 2011-03-01 2017-10-27 Univ Yale Prediccion de neoplasmas neuroendocrinos gastroenteropancreaticos (gep-nens).
PL3194618T3 (pl) 2014-09-15 2021-12-13 Clifton Life Sciences LLC Kompozycje, sposoby i zestawy do diagnozy nowotworu neuroendokrynnego żołądkowo- jelitowo-trzustkowego
CN111479931B (zh) 2017-11-30 2024-08-16 液体活检研究有限责任公司 使用基因表达测定预测肽受体放射治疗

Also Published As

Publication number Publication date
CN111479931A (zh) 2020-07-31
US20190160189A1 (en) 2019-05-30
JP2023164922A (ja) 2023-11-14
CA3080750A1 (en) 2019-06-06
US11744907B2 (en) 2023-09-05
JP7344871B2 (ja) 2023-09-14
JP2021503925A (ja) 2021-02-15
BR112020008680A2 (pt) 2020-11-10
WO2019108734A1 (en) 2019-06-06
EP3717667A1 (en) 2020-10-07
KR20200092382A (ko) 2020-08-03
CN111479931B (zh) 2024-08-16
AU2018375376A1 (en) 2020-05-14
US20240042069A1 (en) 2024-02-08
IL274279A (en) 2020-06-30

Similar Documents

Publication Publication Date Title
MX2017014736A (es) Metodos terapeuticos y diagnosticos para cancer.
MX2022009625A (es) Receptores de antigenos quimericos condicionalmente activos para celulas t modificadas.
MX2023002251A (es) Antagonistas de union al eje pd-l1 y usos de los mismos para el tratamiento de cancer.
GB2552267A (en) Detection and treatment of disease exhibiting disease cell heterogeneity and systems and methods for communicating test results
MX2020005657A (es) Predictor de radioterapia de receptor de peptido usando un ensayo de expresion genica.
MX2018008169A (es) Tratamiento de tumores que incorpora isocitrato deshidrogenasa mutante.
MX2018010361A (es) Métodos terapéuticos y de diagnóstico para el cáncer.
TR201907389T4 (tr) Meme kanserinden kaynaklanan metastazlı kemik kanserinin prognozu ve tedavisine yönelik yöntem.
MX2015011362A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
EP3839510A3 (en) Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
AR099856A1 (es) Métodos para diagnosticar y tratar la enfermedad de intestino inflamado
WO2018183817A3 (en) Tumor burden as measured by cell free dna
WO2014184679A3 (en) Method for the prognosis and treatment of renal cell carcinoma metastasis
MX2017004742A (es) Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos.
EP4265740A3 (en) Methods for predicting risk of metastasis in cutaneous melanoma
MX2019014661A (es) Variantes de b4galt1 y usos de estas.
SG10201806729VA (en) Novel assay to detect human periostin
MX2017010516A (es) Biomarcadores para el diagnóstico y pronóstico de trastornos ectáticos de la córnea.
NZ714014A (en) Therapeutic effect prediction method for colorectal cancer patient in whom expression of tk1 protein has increased
MX2017009857A (es) Isoformas delta133p53beta y delta133p53gamma son biomarcadores de celulas madre cancerosas.
WO2015181555A8 (en) Expression profiling for determining the responsiveness of cancers to treatment with an anti-angiogenic agent
MX2018009112A (es) Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer mediante la medicion del nivel de un biomarcador plasmatico.
MX2018015334A (es) Composiciones, dispositivos y métodos de prueba de sensibilidad a los alimentos a la enfermedad de reflujo gastroesofageal.
MX2022003856A (es) Método para predecir los requisitos para terapia biológica.
UA109275U (uk) Спосіб прогнозування розвитку остеопорозу